Ann: MD and CEO Dr Collier presents at BIO Asia T, page-21

re: Ann: MD and CEO Dr Collier presents at BI... "I think the first thing to start with is to recognise that although we’ve made tremendous advances in therapy, still between thirty and forty percent of all patients actually don’t respond to the anti-TNFs that I talked about previously - and further a group of patients will have so severe side affects that they have to stop. So there is still a huge unmet medical need for new therapies, better therapies in the treatment of rheumatic diseases. If you then look at what CBio (INVION) does, we have a new potential medicine called (CPN10). It’s a naturally occurring protein that actually exists in both you and me, and this is slightly modified. What we know is that this protein in its natural state actually protects the body against stress, so it actually activates with stress. We also know that it is a powerful anti inflammatory and as such, we are trying to use that part of its activity. We’ve seen in both animal studies and now in very early studies in man, that it does seem to be very active and very efficacious – and so far we have been fortunate not to see too many serious adverse events either. So we think this has the potential to be a complementary medicine to the anti-TNFs." Novo Nordisk's Dr Ando 2009.